https://www.biopharmawatch.com/news/MPLT/segal-trials-phase-2-zephyr-study BiopharmaWatch en 2026-08-21T15:33:00.000Z Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study https://www.biopharmawatch.com/news/HSDT/solana-company-governance-proposals-hsdt BiopharmaWatch en 2026-08-21T15:00:14.000Z Solana Company Announces Positions and Votes on first Solana Governance Proposals https://www.biopharmawatch.com/news/SRRK/scholar-rock-apitegromab-regulatory-update BiopharmaWatch en 2026-08-21T13:06:00.000Z Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan https://www.biopharmawatch.com/news/ALVO/alvotech-licensing-agreement-lotus-pharmaceutical BiopharmaWatch en 2026-08-21T13:00:00.000Z Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets https://www.biopharmawatch.com/news/DRMA/dermata-preorders-tome-treatment-launch BiopharmaWatch en 2026-08-21T12:30:00.000Z Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch https://www.biopharmawatch.com/news/RNXT/renovorx-regains-nasdaq-compliance-minimum-bid-price BiopharmaWatch en 2026-08-21T12:30:00.000Z RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/GOSS/gossamer-bio-private-placement-seralutinib-fda-approval BiopharmaWatch en 2026-08-21T12:00:00.000Z Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval https://www.biopharmawatch.com/news/AZTR/azitra-regains-compliance-nyse-american BiopharmaWatch en 2026-08-21T12:00:00.000Z Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-ambros-merger-agreement BiopharmaWatch en 2026-08-21T12:00:00.000Z Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-phase-3-trial-etripamil-afib-rvr BiopharmaWatch en 2026-08-21T12:00:00.000Z Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-nasdaq-letter-receipt BiopharmaWatch en 2026-08-21T12:00:00.000Z Synergy CHC Corp. Announces Receipt of Nasdaq Letter https://www.biopharmawatch.com/news/ABBV/abbvie-new-data-wclc-2026-lung-cancer-pipeline BiopharmaWatch en 2026-08-21T11:45:00.000Z AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline https://www.biopharmawatch.com/news/CAPR/kaos-capital-calls-capricor-shareholders BiopharmaWatch en 2026-08-21T11:45:00.000Z Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders https://www.biopharmawatch.com/news/ABUS/arbutus-repurchases-common-shares-tender-offer BiopharmaWatch en 2026-08-21T11:30:00.000Z Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer https://www.biopharmawatch.com/news/JNJ/ec-approves-tecvayli-daratumumab-multiple-myeloma BiopharmaWatch en 2026-08-21T09:40:00.000Z European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care https://www.biopharmawatch.com/news/AVAH/aveanna-secondary-offering-pricing BiopharmaWatch en 2026-08-21T00:16:00.000Z Aveanna Announces Pricing of Secondary Offering of Common Stock https://www.biopharmawatch.com/news/MDT/medtronic-cash-dividend-fiscal-year-2027 BiopharmaWatch en 2026-08-20T20:50:00.000Z Medtronic announces cash dividend for second quarter of fiscal year 2027 https://www.biopharmawatch.com/news/HCA/hca-healthcare-september-conferences-2026 BiopharmaWatch en 2026-08-20T20:30:00.000Z HCA Healthcare, Inc. to Present at September Conferences https://www.biopharmawatch.com/news/IQV/iqvia-ai-clinical-decision-support-tool-award BiopharmaWatch en 2026-08-20T20:15:00.000Z IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year https://www.biopharmawatch.com/news/AVAH/aveanna-secondary-offering-common-stock BiopharmaWatch en 2026-08-20T20:09:00.000Z Aveanna Announces Launch of Secondary Offering of Common Stock https://www.biopharmawatch.com/news/ENSG/ensign-group-credit-facility-increase-800-million BiopharmaWatch en 2026-08-20T20:07:00.000Z The Ensign Group Increases Credit Facility to $800 Million and Extends Maturity https://www.biopharmawatch.com/news/NXGL/nexgel-leadership-transition-strategic-review BiopharmaWatch en 2026-08-20T20:05:00.000Z NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE https://www.biopharmawatch.com/news/ISPC/ispecimen-completes-international-cancer-research-order BiopharmaWatch en 2026-08-20T20:05:00.000Z iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks https://www.biopharmawatch.com/news/UFPT/ufp-technologies-midwest-ideas-investor-conference-2026 BiopharmaWatch en 2026-08-20T17:55:00.000Z UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the 17th Annual Midwest IDEAS Investor Conference on August 26th in Chicago, IL https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-opens-sleep-facility-nevada BiopharmaWatch en 2026-08-20T14:24:00.000Z Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment https://www.biopharmawatch.com/news/COSM/cosmos-health-exclusive-distribution-agreement-saudi-arabia BiopharmaWatch en 2026-08-20T13:30:00.000Z Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term https://www.biopharmawatch.com/news/PLRZ/polyrizon-completes-nasarix-study-site-network BiopharmaWatch en 2026-08-20T13:30:00.000Z Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment https://www.biopharmawatch.com/news/CELZ/creative-medical-completes-adapt-trial-enrollment BiopharmaWatch en 2026-08-20T13:15:00.000Z Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning https://www.biopharmawatch.com/news/BMY/chai-discovery-collaboration-bms-ai-antibody-discovery BiopharmaWatch en 2026-08-20T13:00:00.000Z Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery https://www.biopharmawatch.com/news/LFST/lifestance-health-foundation-afsp-partnership-renewal BiopharmaWatch en 2026-08-20T13:00:00.000Z LifeStance Health Foundation Renews Partnership with the American Foundation for Suicide Prevention to Advance Mental Health Research https://www.biopharmawatch.com/news/IVF/invo-fertility-prp-research-midwest-symposium-2026 BiopharmaWatch en 2026-08-20T13:00:00.000Z INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-patent-allowance-art27-13 BiopharmaWatch en 2026-08-20T12:52:00.000Z Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-expands-tru-niagen-retail-footprint BiopharmaWatch en 2026-08-20T12:32:00.000Z Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club https://www.biopharmawatch.com/news/FBLG/fibrobiologics-australian-patent-cannabidiol-therapy BiopharmaWatch en 2026-08-20T12:30:00.000Z FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-20T12:30:00.000Z Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/PFSA/profusa-q2-2026-results-g3-vision-labs-option-agreement BiopharmaWatch en 2026-08-20T12:30:00.000Z Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company https://www.biopharmawatch.com/news/SLGL/sol-gel-q2-2026-financial-results-corporate-updates BiopharmaWatch en 2026-08-20T12:30:00.000Z Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/RNXT/renovorx-us-patent-allowance-renovocath-drug-delivery BiopharmaWatch en 2026-08-20T12:30:00.000Z RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment https://www.biopharmawatch.com/news/HYPR/hyperfine-fda-clearance-optive-ai-software BiopharmaWatch en 2026-08-20T12:15:00.000Z Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings https://www.biopharmawatch.com/news/ICCM/icecure-choicem-study-breast-cancer-cryoablation BiopharmaWatch en 2026-08-20T12:10:00.000Z West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-fda-fast-track-lti-03-ipf BiopharmaWatch en 2026-08-20T12:00:17.000Z Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-painweek-2026-symposium BiopharmaWatch en 2026-08-20T12:00:00.000Z Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium https://www.biopharmawatch.com/news/CRL/charles-river-medigen-vaccine-collaboration BiopharmaWatch en 2026-08-20T12:00:00.000Z Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reverse-stock-split-2026 BiopharmaWatch en 2026-08-20T12:00:00.000Z bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-gx-03-skin-inflammation-research BiopharmaWatch en 2026-08-20T12:00:00.000Z Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch https://www.biopharmawatch.com/news/ADAG/adagene-participate-investor-conferences-2026 BiopharmaWatch en 2026-08-20T12:00:00.000Z Adagene to Participate in Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-baird-morgan-stanley-conferences BiopharmaWatch en 2026-08-20T12:00:00.000Z Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-phase-1-2a-lithium-neuroimaging-data BiopharmaWatch en 2026-08-20T12:00:00.000Z Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC https://www.biopharmawatch.com/news/NUVB/nuvation-bio-fda-fast-track-safusidenib-idh1-glioma BiopharmaWatch en 2026-08-20T12:00:00.000Z Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma https://www.biopharmawatch.com/news/CYTK/cytokinetics-esc-congress-2026-presentations BiopharmaWatch en 2026-08-20T11:30:00.000Z Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/CNSY/cerenome-sno-asco-conference-2026 BiopharmaWatch en 2026-08-20T11:30:00.000Z Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines https://www.biopharmawatch.com/news/IFRX/inflarx-participation-september-investor-conferences BiopharmaWatch en 2026-08-20T11:30:00.000Z InflaRx Announces Participation in September Investor Conferences https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-q2-2026-results BiopharmaWatch en 2026-08-20T11:30:00.000Z Evaxion announces business update and second quarter 2026 financial results https://www.biopharmawatch.com/news/URGN/intragel-urogen-collaboration-advance-oncology-therapies BiopharmaWatch en 2026-08-20T11:05:00.000Z IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies https://www.biopharmawatch.com/news/URGN/urogen-strategic-collaboration-intragel-oncology BiopharmaWatch en 2026-08-20T11:00:00.000Z UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline https://www.biopharmawatch.com/news/IONS/ionis-new-data-severe-hypertriglyceridemia-esc-2026 BiopharmaWatch en 2026-08-20T11:00:00.000Z Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 https://www.biopharmawatch.com/news/ACON/aclarion-university-arizona-clarity-trial-site BiopharmaWatch en 2026-08-20T11:00:00.000Z Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site https://www.biopharmawatch.com/news/GUTS/fractyl-health-commercial-strategy-day-revita-therapy BiopharmaWatch en 2026-08-20T11:00:00.000Z Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-wes-burwell-chro BiopharmaWatch en 2026-08-20T11:00:00.000Z Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer https://www.biopharmawatch.com/news/NBP/novabridge-first-half-2026-financial-results BiopharmaWatch en 2026-08-20T11:00:00.000Z NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution https://www.biopharmawatch.com/news/HROW/harrow-iheezo-data-patient-discomfort-intravitreal-injections BiopharmaWatch en 2026-08-20T11:00:00.000Z Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections https://www.biopharmawatch.com/news/ACIU/aci-19764-positive-phase-1-data BiopharmaWatch en 2026-08-20T11:00:00.000Z AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-advances-rad202-phase-1-trial BiopharmaWatch en 2026-08-20T11:00:00.000Z Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial https://www.biopharmawatch.com/news/BNTX/biontech-wclc-2026-lung-cancer-pipeline-progress BiopharmaWatch en 2026-08-20T09:30:00.000Z BioNTech präsentiert auf der WCLC 2026 Fortschritte ihrer spätklinischen Pipeline bei Lungenkrebs und erste globale Daten zur innovativen Behandlungskombination aus Pumitamig und Elfetabart Drozuntecan https://www.biopharmawatch.com/news/BNTX/biontech-lung-cancer-pipeline-wclc-2026 BiopharmaWatch en 2026-08-20T09:30:00.000Z BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-upsized-public-offering BiopharmaWatch en 2026-08-20T03:06:00.000Z Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock https://www.biopharmawatch.com/news/EDSA/edesa-biotech-pricing-public-offering BiopharmaWatch en 2026-08-20T02:20:00.000Z Edesa Biotech Announces Pricing of $25.0 Million Public Offering https://www.biopharmawatch.com/news/TLX/telix-2026-half-year-results-commercial-execution BiopharmaWatch en 2026-08-20T00:32:00.000Z Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline https://www.biopharmawatch.com/news/PMI/picard-medical-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-19T21:30:00.000Z Picard Medical Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-approval-genglycos-gsdia BiopharmaWatch en 2026-08-19T21:22:00.000Z Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-approval-genglycos-gsdia BiopharmaWatch en 2026-08-19T21:22:00.000Z Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-jefferies-conference-2026 BiopharmaWatch en 2026-08-19T20:30:00.000Z Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-webcast-fy2026-results BiopharmaWatch en 2026-08-19T20:30:00.000Z Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results https://www.biopharmawatch.com/news/SERA/sera-prognostics-appoints-scott-gleason-cfo BiopharmaWatch en 2026-08-19T20:30:00.000Z SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-business-update-2026 BiopharmaWatch en 2026-08-19T20:30:00.000Z Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-nirav-jhaveri-cfo BiopharmaWatch en 2026-08-19T20:05:00.000Z Longeveron Appoints Nirav Jhaveri as Chief Financial Officer https://www.biopharmawatch.com/news/MMSI/merit-medical-global-operations-leadership-transition BiopharmaWatch en 2026-08-19T20:05:00.000Z Merit Medical Announces Global Operations Leadership Transition https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2026-results BiopharmaWatch en 2026-08-19T20:05:00.000Z Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results https://www.biopharmawatch.com/news/EDSA/edesa-biotech-proposed-public-offering BiopharmaWatch en 2026-08-19T20:01:00.000Z Edesa Biotech Announces Proposed Public Offering